Effects of switching to aripiprazole from current atypical antipsychotics on subsyndromal symptoms and tolerability in patients with bipolar disorder.

Abstract	We evaluated the effectiveness of aripiprazole among bipolar patients who had switched to this medication as a result of difficulty maintaining on their prestudy atypical antipsychotics (AAPs) because of subsyndromal mood symptoms or intolerance. This study included 77 bipolar patients who were in syndromal remission with an AAP as monotherapy or with an AAP combined with a mood stabilizer(s) who needed to switch from their present AAP because of subsyndromal symptoms or intolerance. At 24 weeks after switching to aripiprazole, the remission rates on the Montgomery-Åsberg Depression Rating Scale (MADRS) and on both the MADRS and the Young Mania Rating Scale were increased significantly in the full sample and in the inefficacy subgroup. In the inefficacy subgroup, the MADRS score change was significant during the 24 weeks of study. Total cholesterol and prolactin decreased significantly after switching to aripiprazole. The proportion of patients who had abnormal values for central obesity and hypercholesterolemia decreased significantly from baseline to week 24. These findings suggest that a change from the current AAP to aripiprazole was associated with improvement in subsyndromal mood symptoms and several lipid/metabolic or safety profile parameters in patients with bipolar disorder with tolerability concerns or subsyndromal mood symptoms.
Authors	Young Sup Woo, Won-Myong Bahk, Young-Min Park, Sangkeun Chung, Bo-Hyun Yoon, Seunghee Won, Jeong Goo Lee, Hwang-Bin Lee, Won Kim, Jong-Hyun Jeong, Kwanghun Lee, Moon-Doo Kim
Journal	International clinical psychopharmacology (Int Clin Psychopharmacol) Vol. 31 Issue 5 Pg. 275-86 (09 2016) ISSN: 1473-5857 [Electronic] England
PMID	27487259 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References	Antipsychotic Agents Aripiprazole
Topics	Adult Antipsychotic Agents (adverse effects, therapeutic use) Aripiprazole (adverse effects, therapeutic use) Bipolar Disorder (diagnosis, drug therapy) Body Weight (drug effects) Drug Substitution (trends) Female Follow-Up Studies Humans Hypercholesterolemia (chemically induced) Male Middle Aged Prospective Studies Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!